Since its founding in 1994, the Case Western Reserve University/University Hospitals Case Medical Center (UHCMC) Center for AIDS Research (CWRU/UH CFAR) has been a source of excellence for both clinical and basic AIDS research. The CWRU/UH CFAR currently has 102 Full Members, 53 Associate CFAR members, who are students, postdoctoral fellows and research associates, and 21 International Members. Members are drawn from the CWRU School of Medicine, UHCMC, MetroHealth Medical Center, the Cleveland Clinic Foundation, the Louis Stokes Cleveland Veterans Administration Medical Center and the Joint Clinical Research Center (JCRC) in Kampala Uganda. Major strengths in the CWRU/UH CFAR include international research based on our 26-year research collaboration with Uganda, immune pathogenesis, basic virology and Cure research, and clinical trials. The CWRU/UH CFAR has the following Specific Aims: Provide scientific and administrative leadership to position the CWRU/UH CFAR at the forefront of HIV research (Administrative Core A). Conduct a responsive pilot grants program that accelerates junior faculty development and support for the next generation of HIV investigators (Developmental Core B). Support cutting edge research in Uganda by leveraging expertise from all CFAR Cores and programs (Uganda Laboratory Core C). As the first CFAR to make a major investment in international research, the CFAR operates one of the most advanced scientific laboratories in Sub-Saharan Africa. Support translational research through access to unique clinical specimens (Clinical Services Core D). Maintain a research infrastructure to support innovative multidisciplinary HIV research (Virology, Next Generation Sequencing and Imaging Core E, Immune Function Core F, Proteomics and Systems Biology Core G). To inform and engage CFAR and community members in our basic and clinical research programs and provide training, especially for minorities (Administrative Core A and Developmental Core B). Promote the national CFAR agenda by participating in collaborative research programs and assuming leadership in CFAR initiatives (Administrative Core A). In summary, through its scientific leadership, mentoring, pilot funding, scientific Cores, community outreach, and unique program in Uganda, the CFAR has effectively positioned its investigators at the leading edge of HIV/AIDS research. Although we remain relatively small, even as a tier-three CFAR we have been able to offer a range of Core services and activities that rival and often exceed those of much larger CFARs at other institutions.

Public Health Relevance

The HIV/AIDS pandemic is the single largest threat to global public health. The Case CFAR creates a collaborative environment that strongly supports HIV research at CWRU and for our colleagues working in Uganda and in other CFARs in the national network.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI036219-25S1
Application #
10155682
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Beaubien, Candice M
Project Start
1997-04-01
Project End
2021-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
25
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications